The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Radioprotective and locomotor responses of mice treated with nimodipine alone and in combination with WR-151327.

The effect of combining a radiation-protective phosphorothioate with another agent was investigated in an attempt to increase radioprotection and reduce toxicity. The calcium channel blocker nimodipine (NIMO) was administered alone (1 or 10 mg kg-1) or in combination with 200 mg kg-1 of the phosphorothioate radioprotector WR-151327 (WR) (S-3-(3-methylaminopropylamino)propylphosphorothioic acid). Radioprotection as measured (30-day survival) of mice treated i.p. 30 min before (60)Co irradiation at a dose rate of 1 Gy min-1 was evaluated in CD2F1 male mice. The effects of nimodipine and WR-151327 on locomotor activity were investigated also in a separate group of non-irradiated mice. The LD(50/30) for the Emulphor vehicle control group was 8.56. For nimodipine alone (1 or 10 mg kg-1) the LD(50/30)was 8.39 and 10.21 Gy, respectively, yielding dose modification factors (DMFs) of 0.98 and 1.19, respectively. When WR-151327 was given alone, the <LD(50/30) was 12.48 Gy (DMF = 1.46; P < 0.05 from vehicle). WR-151327 combined with 1 or 10 mg kg-1 nimodipine resulted in an LD(50/30) of 12.73 Gy (DMF 1.49, P < 0.05 from vehicle), and when WR-151327 was combined with 10 mg kg-1 nimodipine the LD(50/30) was 14.29 Gy (DMF = 1.67, P < 0.001 from WR-151327). For either dose of nimodipine, locomotor activity did not differ from vehicle. WR-151327 and WR-151327 + 1 mg kg-1 nimodipine resulted in locomotor decrements for up to 4 h post-administration (P < 0.05 from vehicle), and WR-151327 + 10 mg kg-1 nimodipine for up to 6 h (P < 0.05 from WR-151327). Therefore, although there was an additive radioprotective effect when the higher dose of nimodipine was combined with WR-151327, the locomotor decrement was also enhanced. These results demonstrate that a combination of nimodipine and a phosphorothioate such as WR-151327 may be useful as a clinical setting where behavioral and physiological side-effects can be monitored. Published in 2001 by John Wiley & Sons, Ltd.[1]


  1. Radioprotective and locomotor responses of mice treated with nimodipine alone and in combination with WR-151327. Landauer, M.R., Castro, C.A., Benson, K.A., Hogan, J.B., Weiss, J.F. Journal of applied toxicology : JAT. (2001) [Pubmed]
WikiGenes - Universities